Biomaterials for Abrogating Metastasis: Bridging the Gap between Basic and Translational Research.

Area of Science:

• Oncology
• Nanomedicine
• Materials Science

Background:

• Cancer metastasis remains a significant challenge in oncology.
• Current therapeutic strategies lack efficient and standardized delivery to metastatic sites.
• A paradigm shift is needed to effectively treat cancer spread.

Purpose of the Study:

• To propose novel nanomedicine-based strategies for cancer metastasis therapy.
• To address the need for targeted and stage-specific treatment of metastatic cancer.
• To bridge the gap between basic research and clinical translation in metastasis therapeutics.

Main Methods:

• Leveraging advancements in materials design and nanotechnology.
• Implementing three distinct therapeutic strategies: local primary tumor abrogation, primary tumor reprogramming, and combination therapy.
• Considering optimal administration routes for each strategy.

Main Results:

• The proposed strategies aim to differentially combat cancer spread at primary tumor growth and metastasis formation stages.
• Nanotechnology enables targeted delivery of therapeutic cargo to metastatic sites.
• The strategies are adaptable based on cancer type and disease state.

Conclusions:

• Nanomedicine holds significant potential for developing focused and efficacious cancer metastasis therapeutics.
• A multi-pronged approach, tailored to disease stage, is crucial for combating metastasis.
• Translational research is vital to bring these advanced nanomedicine strategies to clinical practice.